Ranexa

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2006-2012
02420062012

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Priority Application: US61/361056 Priority Date: July 2, 2010 Inventors: Kobayashi, Tetsuya; Koltun, Dmitry; Notte, Gregory… (More)
Is this relevant?
2011
2011
We report the case of a renal transplant patient on tacrolimus who developed a fully reversible renal failure and a doubling in… (More)
  • figure 1
Is this relevant?
Review
2010
Review
2010
Ischemic heart disease is the major cause of morbidity and mortality in the Western world. Patients often suffer a reduction in… (More)
Is this relevant?
Review
2008
Review
2008
Extended-release ranolazine (ranolazine ER) [Ranexa] is a piperazine derivative with a novel mechanism of action that was… (More)
  • table I
  • table II
  • table III
  • figure 1
Is this relevant?
2007
2007
  • S Ndegwa
  • Issues in emerging health technologies
  • 2007
(1) Ranolazine-- an adjunctive treatment to beta-blockers, calcium channel blockers, or long-acting nitrates-- is indicated for… (More)
Is this relevant?
2007
2007
488 P&T® • September 2007 • Vol. 32 No. 9 INTRODUCTION Angina pectoris (chest pain) is a clinical syndrome characterized by… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
2006
2006
  • The Medical letter on drugs and therapeutics
  • 2006
 
Is this relevant?
2006
2006
Ranolazine (Ranexa; Cardiovascular Therapeutics) was approved by the US FDA for the treatment of chronic angina in January 2006… (More)
Is this relevant?
Review
2006
Review
2006
Ranolazine (Ranexa), a piperazine derivative, is a new antianginal agent approved for the treatment of chronic stable angina… (More)
Is this relevant?
Review
2006
Review
2006
Ranolazine (Ranexa), a piperazine derivative, is a new antianginal agent approved for the treatment of chronic stable angina… (More)
Is this relevant?